Alnylam Pharmaceuticals
ALNY
#1134
Rank
HK$155.30 B
Marketcap
HK$1,160
Share price
-1.06%
Change (1 day)
-67.68%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): HK$155.36

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is HK$155.40. In 2025 the company made an earnings per share (EPS) of HK$13.81.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$155.361025.31%
2025HK$13.81
2023-HK$27.69-62%
2022-HK$72.8729.03%
2021-HK$56.48-3.36%
2020-HK$58.44-8.48%
2019-HK$63.857.67%
2018-HK$59.3039.74%
2017-HK$42.4412.94%
2016-HK$37.5738.84%
2015-HK$27.06-32.88%
2014-HK$40.32259.44%
2013-HK$11.22-31.25%
2012-HK$16.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
HK$41.18-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$15.54-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$368.53 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$20.63-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$5.73-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.49-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$3.53-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-HK$26.12-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA